Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 325 to 336 of 336 entries
Sorted by: Best Match Show Resources per page
Radiomics for precision medicine in glioblastoma.

Journal of neuro-oncology

Aftab K, Aamir FB, Mallick S, Mubarak F, Pope WB, Mikkelsen T, Rock JP, Enam SA.
PMID: 35020109
J Neurooncol. 2022 Jan 12; doi: 10.1007/s11060-021-03933-1. Epub 2022 Jan 12.

INTRODUCTION: Being the most common primary brain tumor, glioblastoma presents as an extremely challenging malignancy to treat with dismal outcomes despite treatment. Varying molecular epidemiology of glioblastoma between patients and intra-tumoral heterogeneity explains the failure of current one-size-fits-all treatment...

Cite
Aftab K, Aamir FB, Mallick S, et al. Radiomics for precision medicine in glioblastoma. J Neurooncol. 2022;doi: 10.1007/s11060-021-03933-1.
Aftab, K., Aamir, F. B., Mallick, S., Mubarak, F., Pope, W. B., Mikkelsen, T., Rock, J. P., & Enam, S. A. (2022). Radiomics for precision medicine in glioblastoma. Journal of neuro-oncology, . https://doi.org/10.1007/s11060-021-03933-1
Aftab, Kiran, et al. "Radiomics for precision medicine in glioblastoma." Journal of neuro-oncology vol. (2022). doi: https://doi.org/10.1007/s11060-021-03933-1
Aftab K, Aamir FB, Mallick S, Mubarak F, Pope WB, Mikkelsen T, Rock JP, Enam SA. Radiomics for precision medicine in glioblastoma. J Neurooncol. 2022 Jan 12; doi: 10.1007/s11060-021-03933-1. Epub 2022 Jan 12. PMID: 35020109.
Copy Download .nbib Format: NLM
Proposed definition of competencies for surgical neuro-oncology training.

Journal of neuro-oncology

Kamp MA, Malzkorn B, von Sass C, DiMeco F, Hadjipanayis CG, Senft C, Rapp M, Gepfner-Tuma I, Fountas K, Krieg SM, Neukirchen M, Florian IȘ, Schnell O, Mijderwijk HJ, Perin A, Baumgarten P, van Lieshout JH, Thon N, Renovanz M, Kahlert U, Spoor JKH, Hänggi D, McLean AL, Mäurer M, Sarrubbo S, Freyschlag CF, Schmidt NO, Vergani F, Jungk C, Stein M, Forster MT, Weinberg JS, Sinclair J, Belykh E, Bello L, Mandonnet E, Moiyadi A, Sabel M.
PMID: 33881726
J Neurooncol. 2021 May;153(1):121-131. doi: 10.1007/s11060-021-03750-6. Epub 2021 Apr 21.

OBJECTIVE: The aim of this work is to define competencies and entrustable professional activities (EPAs) to be imparted within the framework of surgical neuro-oncological residency and fellowship training as well as the education of medical students. Improved and specific...

Cite
Kamp MA, Malzkorn B, von Sass C, et al. Proposed definition of competencies for surgical neuro-oncology training. J Neurooncol. 2021;153(1):121-131doi: 10.1007/s11060-021-03750-6.
Kamp, M. A., Malzkorn, B., von Sass, C., DiMeco, F., Hadjipanayis, C. G., Senft, C., Rapp, M., Gepfner-Tuma, I., Fountas, K., Krieg, S. M., Neukirchen, M., Florian, I. �. �., Schnell, O., Mijderwijk, H. J., Perin, A., Baumgarten, P., van Lieshout, J. H., Thon, N., Renovanz, M., Kahlert, U., Spoor, J. K. H., Hänggi, D., McLean, A. L., Mäurer, M., Sarrubbo, S., Freyschlag, C. F., Schmidt, N. O., Vergani, F., Jungk, C., Stein, M., Forster, M. T., Weinberg, J. S., Sinclair, J., Belykh, E., Bello, L., Mandonnet, E., Moiyadi, A., & Sabel, M. (2021). Proposed definition of competencies for surgical neuro-oncology training. Journal of neuro-oncology, 153(1), 121-131. https://doi.org/10.1007/s11060-021-03750-6
Kamp, Marcel A, et al. "Proposed definition of competencies for surgical neuro-oncology training." Journal of neuro-oncology vol. 153,1 (2021): 121-131. doi: https://doi.org/10.1007/s11060-021-03750-6
Kamp MA, Malzkorn B, von Sass C, DiMeco F, Hadjipanayis CG, Senft C, Rapp M, Gepfner-Tuma I, Fountas K, Krieg SM, Neukirchen M, Florian IȘ, Schnell O, Mijderwijk HJ, Perin A, Baumgarten P, van Lieshout JH, Thon N, Renovanz M, Kahlert U, Spoor JKH, Hänggi D, McLean AL, Mäurer M, Sarrubbo S, Freyschlag CF, Schmidt NO, Vergani F, Jungk C, Stein M, Forster MT, Weinberg JS, Sinclair J, Belykh E, Bello L, Mandonnet E, Moiyadi A, Sabel M. Proposed definition of competencies for surgical neuro-oncology training. J Neurooncol. 2021 May;153(1):121-131. doi: 10.1007/s11060-021-03750-6. Epub 2021 Apr 21. PMID: 33881726; PMCID: PMC8131302.
Copy Download .nbib Format: NLM
Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review.

Journal of neuro-oncology

Lee EJ, Choi KS, Park ES, Cho YH.
PMID: 34268640
J Neurooncol. 2021 Aug;154(1):25-34. doi: 10.1007/s11060-021-03805-8. Epub 2021 Jul 15.

PURPOSE: Since frameless stereotactic radiosurgery (SRS) techniques have been recently introduced, hypofractionated SRS (HF-SRS) for large brain metastases (BMs) is gradually increasing. To verify the efficacy and safety of HF-SRS for large BMs, we aimed to perform a systematic...

Cite
Lee EJ, Choi KS, Park ES, et al. Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review. J Neurooncol. 2021;154(1):25-34doi: 10.1007/s11060-021-03805-8.
Lee, E. J., Choi, K. S., Park, E. S., & Cho, Y. H. (2021). Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review. Journal of neuro-oncology, 154(1), 25-34. https://doi.org/10.1007/s11060-021-03805-8
Lee, Eun Jung, et al. "Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review." Journal of neuro-oncology vol. 154,1 (2021): 25-34. doi: https://doi.org/10.1007/s11060-021-03805-8
Lee EJ, Choi KS, Park ES, Cho YH. Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review. J Neurooncol. 2021 Aug;154(1):25-34. doi: 10.1007/s11060-021-03805-8. Epub 2021 Jul 15. PMID: 34268640.
Copy Download .nbib Format: NLM
Evaluation of Ac-Lys.

Journal of neuro-oncology

Dijkstra BM, de Jong M, Stroet MCM, Andreae F, Dulfer SE, Everts M, Kruijff S, Nonnekens J, den Dunnen WFA, Kruyt FAE, Groen RJM.
PMID: 33768405
J Neurooncol. 2021 Jun;153(2):211-222. doi: 10.1007/s11060-021-03739-1. Epub 2021 Mar 26.

PURPOSE: Meningioma recurrence rates can be reduced by optimizing surgical resection with the use of intraoperative molecular fluorescence guided surgery (MFGS). We evaluated the potential of the fluorescent tracer 800CW-TATE for MFGS using in vitro and in vivo models....

Cite
Dijkstra BM, de Jong M, Stroet MCM, et al. Evaluation of Ac-Lys. J Neurooncol. 2021;153(2):211-222doi: 10.1007/s11060-021-03739-1.
Dijkstra, B. M., de Jong, M., Stroet, M. C. M., Andreae, F., Dulfer, S. E., Everts, M., Kruijff, S., Nonnekens, J., den Dunnen, W. F. A., Kruyt, F. A. E., & Groen, R. J. M. (2021). Evaluation of Ac-Lys. Journal of neuro-oncology, 153(2), 211-222. https://doi.org/10.1007/s11060-021-03739-1
Dijkstra, Bianca M, et al. "Evaluation of Ac-Lys." Journal of neuro-oncology vol. 153,2 (2021): 211-222. doi: https://doi.org/10.1007/s11060-021-03739-1
Dijkstra BM, de Jong M, Stroet MCM, Andreae F, Dulfer SE, Everts M, Kruijff S, Nonnekens J, den Dunnen WFA, Kruyt FAE, Groen RJM. Evaluation of Ac-Lys. J Neurooncol. 2021 Jun;153(2):211-222. doi: 10.1007/s11060-021-03739-1. Epub 2021 Mar 26. PMID: 33768405; PMCID: PMC8211583.
Copy Download .nbib Format: NLM
Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.

Journal of neuro-oncology

Cho YA, Kim D, Lee B, Shim JH, Suh YL.
PMID: 33864561
J Neurooncol. 2021 May;153(1):43-53. doi: 10.1007/s11060-021-03710-0. Epub 2021 Apr 17.

BACKGROUND: Glioblastoma (GBM) is the most common and malignant gliomas of adults and recur, resulting in death, despite surgery, radiotherapy, and temozolomide-based chemotherapy. There are a few reports on immunotherapy for the mismatch repair (MMR)-deficient GBMs with high tumor...

Cite
Cho YA, Kim D, Lee B, et al. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas. J Neurooncol. 2021;153(1):43-53doi: 10.1007/s11060-021-03710-0.
Cho, Y. A., Kim, D., Lee, B., Shim, J. H., & Suh, Y. L. (2021). Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas. Journal of neuro-oncology, 153(1), 43-53. https://doi.org/10.1007/s11060-021-03710-0
Cho, Yoon Ah, et al. "Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas." Journal of neuro-oncology vol. 153,1 (2021): 43-53. doi: https://doi.org/10.1007/s11060-021-03710-0
Cho YA, Kim D, Lee B, Shim JH, Suh YL. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas. J Neurooncol. 2021 May;153(1):43-53. doi: 10.1007/s11060-021-03710-0. Epub 2021 Apr 17. PMID: 33864561.
Copy Download .nbib Format: NLM
NIH funding trends for neurosurgeon-scientists from 1993-2017: Biomedical workforce implications for neurooncology.

Journal of neuro-oncology

ReFaey K, Freeman WD, Tripathi S, Guerrero-Cazares H, Eatz TA, Meschia JF, Carter RE, Petrucelli L, Meyer FB, Quinones-Hinojosa A.
PMID: 34232472
J Neurooncol. 2021 Aug;154(1):51-62. doi: 10.1007/s11060-021-03797-5. Epub 2021 Jul 07.

INTRODUCTION: Neurosurgeons represent 0.5% of all physicians and currently face a high burden of disease. Physician-scientists are essential to advance the mission of National Academies of Science (NAS) and National Institutes of Health (NIH) through discovery and bench to...

Cite
ReFaey K, Freeman WD, Tripathi S, et al. NIH funding trends for neurosurgeon-scientists from 1993-2017: Biomedical workforce implications for neurooncology. J Neurooncol. 2021;154(1):51-62doi: 10.1007/s11060-021-03797-5.
ReFaey, K., Freeman, W. D., Tripathi, S., Guerrero-Cazares, H., Eatz, T. A., Meschia, J. F., Carter, R. E., Petrucelli, L., Meyer, F. B., & Quinones-Hinojosa, A. (2021). NIH funding trends for neurosurgeon-scientists from 1993-2017: Biomedical workforce implications for neurooncology. Journal of neuro-oncology, 154(1), 51-62. https://doi.org/10.1007/s11060-021-03797-5
ReFaey, Karim, et al. "NIH funding trends for neurosurgeon-scientists from 1993-2017: Biomedical workforce implications for neurooncology." Journal of neuro-oncology vol. 154,1 (2021): 51-62. doi: https://doi.org/10.1007/s11060-021-03797-5
ReFaey K, Freeman WD, Tripathi S, Guerrero-Cazares H, Eatz TA, Meschia JF, Carter RE, Petrucelli L, Meyer FB, Quinones-Hinojosa A. NIH funding trends for neurosurgeon-scientists from 1993-2017: Biomedical workforce implications for neurooncology. J Neurooncol. 2021 Aug;154(1):51-62. doi: 10.1007/s11060-021-03797-5. Epub 2021 Jul 07. PMID: 34232472; PMCID: PMC8684039.
Copy Download .nbib Format: NLM
Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas.

Journal of neuro-oncology

Fujita Y, Nagashima H, Tanaka K, Hashiguchi M, Itoh T, Sasayama T.
PMID: 34550511
J Neurooncol. 2021 Oct;155(1):81-92. doi: 10.1007/s11060-021-03845-0. Epub 2021 Sep 22.

PURPOSE: Photodynamic therapy (PDT) subsequent to surgical tumor removal is a novel localized treatment for malignant glioma that provides effective local control. The acute response of malignant glioma to PDT can be detected as linear transient hyperintense signal on...

Cite
Fujita Y, Nagashima H, Tanaka K, et al. Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas. J Neurooncol. 2021;155(1):81-92doi: 10.1007/s11060-021-03845-0.
Fujita, Y., Nagashima, H., Tanaka, K., Hashiguchi, M., Itoh, T., & Sasayama, T. (2021). Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas. Journal of neuro-oncology, 155(1), 81-92. https://doi.org/10.1007/s11060-021-03845-0
Fujita, Yuichi, et al. "Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas." Journal of neuro-oncology vol. 155,1 (2021): 81-92. doi: https://doi.org/10.1007/s11060-021-03845-0
Fujita Y, Nagashima H, Tanaka K, Hashiguchi M, Itoh T, Sasayama T. Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas. J Neurooncol. 2021 Oct;155(1):81-92. doi: 10.1007/s11060-021-03845-0. Epub 2021 Sep 22. PMID: 34550511.
Copy Download .nbib Format: NLM
Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience.

Journal of neuro-oncology

Ruttens D, Messiaen J, Ferster A, Piette C, Schifflers S, Van Damme A, van der Werff Ten Bosch J, Verlooy J, Willems L, Jacobs S.
PMID: 33939103
J Neurooncol. 2021 Jun;153(2):293-301. doi: 10.1007/s11060-021-03766-y. Epub 2021 May 03.

INTRODUCTION: Diffuse intrinsic pontine glioma is a rare disease with a high mortality. Our primary aim was to determine the incidence of this disease in Belgium. Secondly, we wanted to compare the treatment approach of Belgian pediatric oncology centres,...

Cite
Ruttens D, Messiaen J, Ferster A, et al. Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience. J Neurooncol. 2021;153(2):293-301doi: 10.1007/s11060-021-03766-y.
Ruttens, D., Messiaen, J., Ferster, A., Piette, C., Schifflers, S., Van Damme, A., van der Werff Ten Bosch, J., Verlooy, J., Willems, L., & Jacobs, S. (2021). Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience. Journal of neuro-oncology, 153(2), 293-301. https://doi.org/10.1007/s11060-021-03766-y
Ruttens, Dries, et al. "Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience." Journal of neuro-oncology vol. 153,2 (2021): 293-301. doi: https://doi.org/10.1007/s11060-021-03766-y
Ruttens D, Messiaen J, Ferster A, Piette C, Schifflers S, Van Damme A, van der Werff Ten Bosch J, Verlooy J, Willems L, Jacobs S. Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience. J Neurooncol. 2021 Jun;153(2):293-301. doi: 10.1007/s11060-021-03766-y. Epub 2021 May 03. PMID: 33939103.
Copy Download .nbib Format: NLM
Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.

Journal of neuro-oncology

Xiao B, Lv SG, Wu MJ, Shen XL, Tu W, Ye MH, Zhu XG.
PMID: 34357490
J Neurooncol. 2021 Sep;154(2):131-144. doi: 10.1007/s11060-021-03814-7. Epub 2021 Aug 06.

BACKGROUND: Circular RNA (circRNA) has been demonstrated to play key roles in regulating glioma progression. Understanding the regulatory mechanism of circRNA in glioma is vital to reveal the pathogenesis of glioma and develop novel therapeutic strategies. Therefore, our study...

Cite
Xiao B, Lv SG, Wu MJ, et al. Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis. J Neurooncol. 2021;154(2):131-144doi: 10.1007/s11060-021-03814-7.
Xiao, B., Lv, S. G., Wu, M. J., Shen, X. L., Tu, W., Ye, M. H., & Zhu, X. G. (2021). Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis. Journal of neuro-oncology, 154(2), 131-144. https://doi.org/10.1007/s11060-021-03814-7
Xiao, Bing, et al. "Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis." Journal of neuro-oncology vol. 154,2 (2021): 131-144. doi: https://doi.org/10.1007/s11060-021-03814-7
Xiao B, Lv SG, Wu MJ, Shen XL, Tu W, Ye MH, Zhu XG. Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis. J Neurooncol. 2021 Sep;154(2):131-144. doi: 10.1007/s11060-021-03814-7. Epub 2021 Aug 06. PMID: 34357490.
Copy Download .nbib Format: NLM
Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas.

Journal of neuro-oncology

Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J.
PMID: 34350560
J Neurooncol. 2021 Sep;154(2):237-246. doi: 10.1007/s11060-021-03819-2. Epub 2021 Aug 04.

PURPOSE: As sphenoid wing meningiomas (SWMs) are associated with varying degrees of bony involvement, we sought to understand potential relationships between genomic subgroup and this feature.METHODS: Patients treated at Yale-New Haven Hospital for SWM were reviewed. Genomic subgroup was...

Cite
Jin L, Youngblood MW, Gupte TP, et al. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. J Neurooncol. 2021;154(2):237-246doi: 10.1007/s11060-021-03819-2.
Jin, L., Youngblood, M. W., Gupte, T. P., Vetsa, S., Nadar, A., Barak, T., Yalcin, K., Aguilera, S. M., Mishra-Gorur, K., Blondin, N. A., Gorelick, E., Omay, S. B., Pointdujour-Lim, R., Judson, B. L., Alperovich, M., Aboian, M. S., McGuone, D., Gunel, M., Erson-Omay, Z., Fulbright, R. K., & Moliterno, J. (2021). Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal of neuro-oncology, 154(2), 237-246. https://doi.org/10.1007/s11060-021-03819-2
Jin, Lan, et al. "Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas." Journal of neuro-oncology vol. 154,2 (2021): 237-246. doi: https://doi.org/10.1007/s11060-021-03819-2
Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. J Neurooncol. 2021 Sep;154(2):237-246. doi: 10.1007/s11060-021-03819-2. Epub 2021 Aug 04. PMID: 34350560.
Copy Download .nbib Format: NLM
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.

Journal of neuro-oncology

Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss SA, Goldberg SB, Aboian MS, Kluger HM, Mahajan A.
PMID: 34351544
J Neurooncol. 2021 Sep;154(2):197-203. doi: 10.1007/s11060-021-03813-8. Epub 2021 Aug 05.

INTRODUCTION: The study aimed to describe the brain metastases (BM) incidence, at diagnosis and follow-up, in patients initially presenting with stage III or IV melanoma and characterize their metastatic brain lesions. We also sought to describe the association of...

Cite
Sandhu MRS, Chiang VL, Tran T, et al. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. J Neurooncol. 2021;154(2):197-203doi: 10.1007/s11060-021-03813-8.
Sandhu, M. R. S., Chiang, V. L., Tran, T., Yu, J. B., Weiss, S. A., Goldberg, S. B., Aboian, M. S., Kluger, H. M., & Mahajan, A. (2021). Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal of neuro-oncology, 154(2), 197-203. https://doi.org/10.1007/s11060-021-03813-8
Sandhu, Mani Ratnesh S, et al. "Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis." Journal of neuro-oncology vol. 154,2 (2021): 197-203. doi: https://doi.org/10.1007/s11060-021-03813-8
Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss SA, Goldberg SB, Aboian MS, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. J Neurooncol. 2021 Sep;154(2):197-203. doi: 10.1007/s11060-021-03813-8. Epub 2021 Aug 05. PMID: 34351544.
Copy Download .nbib Format: NLM
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.

Journal of neuro-oncology

Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M.
PMID: 34322829
J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28.

PURPOSE: Although we have shown the clinical benefit of bevacizumab (BEV) in the treatment of unresectable newly diagnosed glioblastomas (nd-GBM), the relationship between early radiographic response and survival outcome remains unclear. We performed a volumetric study of early radiographic...

Cite
Takigawa K, Hata N, Michiwaki Y, et al. Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. J Neurooncol. 2021;154(2):187-196doi: 10.1007/s11060-021-03812-9.
Takigawa, K., Hata, N., Michiwaki, Y., Hiwatashi, A., Yonezawa, H., Kuga, D., Hatae, R., Sangatsuda, Y., Fujioka, Y., Funakoshi, Y., Otsuji, R., Sako, A., Togao, O., Yoshiura, T., Yoshimoto, K., & Mizoguchi, M. (2021). Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. Journal of neuro-oncology, 154(2), 187-196. https://doi.org/10.1007/s11060-021-03812-9
Takigawa, Kosuke, et al. "Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma." Journal of neuro-oncology vol. 154,2 (2021): 187-196. doi: https://doi.org/10.1007/s11060-021-03812-9
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M. Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. J Neurooncol. 2021 Sep;154(2):187-196. doi: 10.1007/s11060-021-03812-9. Epub 2021 Jul 28. PMID: 34322829; PMCID: PMC8437873.
Copy Download .nbib Format: NLM
Showing 325 to 336 of 336 entries